Proteon Therapeutics grabs $15.2M financing

Waltham, MA-based Proteon Therapeutics has raised $15.2 million in financing, the Boston Business Journal reports, citing SEC documents. The new funding is in exchange for equity and options and follows the company's initiation of a mid-stage trial of its lead drug, PRT-201, which the firm says aims to "improve the outcomes associated with the surgical creation of vascular accesses in chronic kidney disease patients undergoing hemodialysis." Novartis ($NVS) has an option to acquire Proteon after the small firm completes Phase II development of the drug. Report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.